Page 8 - Lobe Sciences News Today

The Investor Summit: Lobe Sciences Invites You to Join Us at the Q2 Virtual Investor Summit Location About Lobe Sciences Lobe is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness. For further information: About the Investor Summit The Investor Su...

Psychedelic-assisted therapy is seeing rapid innovation and investors are taking note as Lobe Sciences (CSE:LOBE, OTC Pink:GTSIF) emerges with new funding, research and development, according to an article published in the Financial Post.  Psychedelic-assisted therapy is seeing rapid innovation and investors are taking note as Lobe Sciences (CSE:LOBE, OTC Pink:GTSIF) emerges with new funding, research and development, according to an article published in the Financial Post.  Based on the arti...

CEO Presenting on the Emerging Growth Conference on April 14; Register now 04/12/2021 | 06:00am EDT Send by mail : Message : Required fields MIAMI, April 12, 2021 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies announces the Schedule of the 5 th Emerging Growth Conference. EmergingGrowth.com is proud to present and welcome you to the 5 th Emerging Growt...

MindMed (OTCQB:MMEDF) released its full-year 2020 financial results.  The company posted a net and comprehensive loss of $35.1 million for the year ended Dec. 31, 2020. Its total assets at the end of the reporting period were $85.6 million, counting $80.1 million in cash. The company used $24.2 million of net cash in operating activities in 2020. Its cash balance as of Tuesday last week hovered at $161 million. The company plans to use the money to improve its portfolio and develop its technol...

Significant Progress Made as Numinus-Sponsored PRIME Study on Psilocybin-Assisted Psychotherapy for Opioid, Stimulant and/or Alcohol Use Disorders Enters Pre-Implementation Stage Numinus Wellness (OTC:LKYSD) and  Syreon Corporation, a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access1 trial of Psilocybin-Research Int...

The Psilocybin Patent Race Is On It feels like these companies are casting a wide net, but it makes sense to file at the beginning of this mushroom mania. Mar 06, 2021 | 12:30 PM EST It seems that a week doesnt go by without a psychedelic company saying it has filed for a patent of some sort. This process can be confusing as the first assumption is that these companies are trying to patent a natural product. It isnt difficult to see how this misunderstanding happens. The headlines shout...

The transaction value of approximately $32,000,000 will significantly improve Lobe's balance sheet with non-dilutive capital and will provide immediate shareholder value Vancouver, British Columbia--(Newsfile

IONIC Brands Corp.: Lobe Sciences Signs Definitive Agreement for Sale of Cowlitz Cannabis Assets to Ionic Brands Corp. VANCOUVER, BC / ACCESSWIRE / February 23, 2021 / Lobe Sciences Ltd. (" Lobe" or the " Company") (LOBE) and Ionic Brands Corp. (" Ionic") (CSE:IONC)(FRA:IB3)(OTC PINK:IONKD) are pleased to announce that, further to their press releases dated December 1, 2020, Lobes wholly owned subsidiary Green Star Biosciences Inc. has signed a definitive binding asset purchase agreement dated ...

Lobe Sciences Ltd.: Lobe Sciences Successfully Completes Proof-of-Concept of Proprietary Nasal Mist Device Vancouver, British Columbia--(Newsfile Corp. - February 18, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (" Lobe" or the " Company") announced today the completion and testing of the proof-of-concept prototype of its proprietary nasal mist device. As announced on December 3, 2020, the Company engaged VisionWorks Engineering of San Diego, CA to complete this first phase of deve...

Small Caps Daily: SmallCapsDaily: Lobe Sciences is a Major Opportunity In the Psychedelics Medicine Industry New York, New York--(Newsfile Corp. - February 12, 2021) - Lobe Sciences Ltd., (OTC Pink: GTSIF), a growth-oriented research, technology & services company that provides financial, management, IP and branding support to businesses, which focuses on the development of psilocybin-based therapeutics for mental health applications, was recently the focus of coverage by leading financial new...